---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-125265"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T07:57:08.670306+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novavax subsidiary agrees to sell Czech manufacturing campus to Novo Nordisk subsidiary for $200M

## Summary
- Total purchase price $200M; $10M credit from September 2024 and $10M escrow released 12 months post-closing.
- Closing conditioned on Czech drug regulator modifying Novavax CZ's manufacturing authorization to reduce scope.
- Novavax CZ continues operations; purchaser reimburses operating costs up to $3.5M per month until closing.
- Customary indemnification; termination right if condition not satisfied within 4 months of signing.
- Transaction involves transfer of land, equipment, contracts, and employees at Bohumil, Jevany facility.

## SEC filing metadata
- accession: 0001104659-24-125265
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924125265/0001104659-24-125265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924125265/tm2430032d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-125265
- JSON: https://secwatch.observer/filing/0001104659-24-125265.json
- Plain text: https://secwatch.observer/filing/0001104659-24-125265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.